( table ; see text ) these include two major areas of focus at the present time : ( 1 ) the use of il-2 +/- lak in combination with a variety of agents which have been shown to be synergistic with it , including other biological response modifiers ( such as interferons ) , agents which may act both as interferon inducers as well as by other mechanisms ( poly-ic : lc and flavone-8-acetic acid ) , and chemotherapeutic agents ( especially cyclophosphamide , doxorubicin and agents which have some activity against the disease being treated such as dtic for melanoma ) , and ( 2 ) various approaches aimed at inducing and expanding tumor-specific immune cells which appear to have greater antitumor activity than lak cells and which may be major contributors to the antitumor efficacy of il-2 therapy .
C0010927
dtic
C0025202
melanoma